AUTL

Autolus Therapeutics Ltd

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics Ltd (AUTL) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.0
Rev Growth YoY N/M
Gross Margin N/M
Price Return 3M 24.2%
Price Return 12M -17.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 481.2
ROE -29.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.4)
2026-08-04 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.4)
2026-08-03 C+ (2.7) C (2.4) C+ (2.7) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C (2.4) C+ (2.7) C (2.4) C- (1.9) C (2.4)
2026-07-29 C+ (2.6) C+ (2.5) D+ (1.7) D+ (1.7) D+ (1.5) C- (2.0)
Page 1 of 2